BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...plays a role in establishing hair cell identity during development. Frequency Therapeutics Inc. (NASDAQ:FREQ) and Sound Pharmaceuticals...
...hearing disorders. “There are things we learned from it,” Jonathan Kil, CEO and CMO of Sound Pharmaceuticals...
...fail because the supporting cell cannot be manipulated like that in the adult.” Jonathon Kil, Sound Pharmaceuticals...
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

...$0.06 on Friday to end the week at $2.19. Sound’s therapy improves hearing in Meniere Sound Pharmaceuticals...
...Tone Audiometry, meeting a primary efficacy endpoint. The selenium-based small molecule, a GPX mimic containing ebselen...
BioCentury | Jun 6, 2018
Distillery Therapeutics

Neurology

...mutant complexed with a library of cysteine-reactive compounds identified the NFE2L2 activator ebselen and an ebselen...
...normal SOD1 folding and testing them in transgenic mouse models of ALS. Sound Pharmaceuticals Inc. has ebselen...
...Inc. has ebselen (SPI-1005) in Phase II testing for hearing loss and Meniere’s disease, and ebselen...
BioCentury | Nov 30, 2017
Clinical News

Sound reports Phase Ib data for SPI-1005 in Meniere's disease

...In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40...
...data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen...
...product is in Phase IIb testing to treat Meniere’s disease. Sound Pharmaceuticals Inc., Seattle, Wash. Product: Ebselen...
BioCentury | Oct 6, 2017
Clinical News

Sound begins Phase IIb of SPI-1005 for Meniere's disease

...Sound Pharmaceuticals Inc. (Seattle, Wash.) began the double-blind, placebo-controlled Phase IIb SPI-1005-251 trial of ebselen (SPI-1005...
...that activates nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2). Sound Pharmaceuticals Inc. , Seattle, Wash. Product: Ebselen...
...disease Endpoint: Safety and hearing loss, tinnitus and vertigo Status: Phase IIb started Milestone: NA Allison Johnson SPI-1005 Sound Pharmaceuticals...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...we've come to recognize two new potential pathways of treating hearing loss." David Weber, Otonomy Sound Pharmaceuticals...
...in 4Q18 for SPI-5557 to treat severe to profound hearing loss. The company’s lead program, ebselen...
...Healthcare Systems Inc., Boston, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Sound Pharmaceuticals...
BioCentury | Jan 25, 2016
Clinical News

Ebselen: Phase Ib started

...twice daily for 21 days in about 40 patients. Sound Pharmaceuticals Inc. , Seattle, Wash. Product: Ebselen...
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB)

...Infectious disease INDICATION: Clostridium In vitro and mouse studies suggest ebselen could be repurposed to treat...
...ebselen decreased toxicity and increased survival compared with vehicle. In a mouse model of CDI, ebselen...
...Next steps could include testing ebselen in additional animal models of CDI. Sound Pharmaceuticals Inc. has ebselen...
BioCentury | Aug 13, 2015
Tools & Techniques

Helping Beethoven hear

...molecule Formulation of the generic steroid dexamethasone Hearing loss associated with Meniere's disease Phase II Sound Pharmaceuticals...
...chemotherapy-induced hearing loss Preclinical Oricula Therapeutics LLC BPN-13661 Small molecule Undisclosed Antibiotic-induced hearing loss Preclinical Sound Pharmaceuticals...
BioCentury | Feb 26, 2015
Translation in Brief

Hearing after cisplatin

...III trials to prevent hearing loss associated with platinum-based chemotherapy in children. Sound Pharmaceuticals Inc. has Ebselen...
Items per page:
1 - 10 of 17